GlassScriptPhysician profile
Kayla Bakane
NPI 1124490073
$11,315.70
in general payments reported to CMS, 2019-2025
50 companies · $2,564 in 2025
The $2,564 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,088 · 2022: $3,044 · 2023: $1,860 · 2024: $1,759 · 2025: $2,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,508 · Consulting Fee: $1,590 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,507.96 |
| Consulting Fee | $1,590.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,279.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,339.85 | 2021-2025 | |
| Lilly USA, LLC | $1,077.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $748.81 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $641.66 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $505.67 | 2021-2024 | Freestyle Libre 3, Jot Dx, Assurity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.43 | 2021-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $436.70 | 2022 | |
| Amgen INC. | $379.96 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $268.83 | 2021-2025 | |
| Corium, LLC | $235.31 | 2022-2024 | Azstarys, Azstarys |
| Antares Pharma, INC. | $232.98 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $226.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $220.06 | 2021-2024 | Veozah |
| Amarin Pharma, INC. | $201.64 | 2021-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $182.35 | 2021-2025 | Verquvo, Dificid, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $164.83 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.62 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $147.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $115.29 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $106.21 | 2021 | |
| Genentech USA, INC. | $105.40 | 2021-2024 | Xolair |
| Daiichi Sankyo INC. | $89.45 | 2021-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $87.48 | 2021-2025 | Xarelto, Spravato |
| Noven Therapeutics, LLC | $73.99 | 2024-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $70.29 | 2022-2024 | Quviviq |
| Eisai INC. | $69.49 | 2021 | |
| Medtronic, INC. | $66.58 | 2024 | Venaseal |
| Dexcom, INC. | $65.62 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.52 | 2021-2024 | Xifaxan |
| Scynexis, INC. | $51.32 | 2022 | |
| Althera Pharmaceuticals LLC | $44.80 | 2022 | |
| Phathom Pharmaceuticals, INC. | $34.59 | 2025 | Voquezna |
| Pulmonx Corporation | $34.22 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Halozyme INC | $32.09 | 2023 | |
| Novartis Pharmaceuticals Corporation | $29.36 | 2021 | |
| Ibsa Pharma INC. | $27.20 | 2021-2023 | Tirosint, Licart |
| Allergan, INC. | $26.99 | 2021 | |
| Jazz Pharmaceuticals INC. | $25.53 | 2022 | |
| Tris Pharma INC | $23.86 | 2023 | Quillivant, Dyanavel Xr, Quillichew Er |
| Corcept Therapeutics | $22.46 | 2025 | Korlym |
| Nevro Corp. | $18.08 | 2023 | Senza |
| Neos Therapeutics, LP | $17.37 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.58 | 2025 | Alvesco |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.25 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $14.36 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2022 | |
| Tersera Therapeutics LLC | $13.53 | 2025 | Quzyttir |
| Currax Pharmaceuticals LLC | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Bakane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.